Prescription drug monitoring programs can be an important tool in limiting opioid addiction, researchers said, but they are most frequently used when they are integrated with a larger electronic health record system.
FDA is delaying indefinitely enforcement of its 5% sales cap on human drug compounders who distribute their products out of state and is suspending its final memorandum of understanding that sought to give state pharmacy boards a key monitoring role over pharmacy compounding.
In a letter sent to FDA chief Robert Califf Wednesday (Oct. 19), four GOP senators demand FDA ramp up focus on development of non-opioid pain medication, the current supply of which is “alarmingly insufficient,” and carry out its mandates under major opioid legislation that was enacted in 2018.
